Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rimegepant for Preemptive Treatment of Trigger-Induced Migraine
NCT07301008Phase 4Recruiting
- Sponsor
- MedStar Health Research Institute
- Start
- Sep 2025
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of rimegepant in migraine, sponsored by MedStar Health Research Institute. Started Sep 2025; status: recruiting.
02
Drugs
rimegepant
03
Conditions
migraine
Beyond the preview
Go deeper on NCT07301008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07301008.